@entity263 . Cluster analysis of patterns with respect to XXXX treatment.

@entity172 @entity1 @entity263 @entity5 @entity3
The responsiveness of @entity263 to treatment with @entity172 has been recognized for over 40 years, but whether the effect is mediated by diminished @entity5 growth or reduction in metastatic spread is not known. To answer this question the authors reviewed the clinical and pathologic features of 89 @entity1 with @entity263 after autopsy. Sixty-three percent of the @entity1 studied were black. @entity1 treated with @entity172 survived somewhat longer (0.05 less than P less than 0.10), but they had significantly greater numbers of metastatic sites (P less than 0.001) and greater overall @entity5 burden (P less than 0.001), with significantly increased frequencies of @entity3 to the liver, adrenal gland, bone, lymph nodes, large bowel, lungs, serosal surfaces, ureters, and central nervous system (CNS) (all P less than 0.05 or lower) compared with @entity1 who had not been treated with @entity172 . However, @entity1 not treated with @entity172 more frequently died from other causes (P less than 0.001). When the @entity1 who died from other causes were excluded from the data analysis, there were no significant differences in the number of metastatic sites between @entity1 who received @entity172 therapy and those who did not, and the only remaining significant difference in the distribution of @entity3 was that @entity1 who received @entity172 treatment had more frequent @entity3 to the adrenal cortex and CNS (P less than 0.05). These observations were corroborated by cluster analysis of the metastatic patterns. Cluster analysis also identified a subset of predominantly (67%) black @entity1 who developed distant @entity3 without much local spread of @entity5 . This suggests that @entity5 behavior in this group was less predictable than for the other @entity1 in whom disease appeared to progress from Stage A to Stage D as expected. The authors conclude that @entity172 therapy may prolong survival by slowing the rate of @entity5 growth rather than by inhibiting the metastatic progression of @entity263 or destroying selective populations of @entity5 cells.
